Spero's SPR741 well tolerated in Phase I

Spero Therapeutics LLC (Cambridge, Mass.) reported data from a Phase I trial in 96 healthy volunteers showing that single and multiple ascending doses of lead potentiator candidate SPR741 were well tolerated. The double-blind, placebo-controlled, Australian trial evaluated the safety and pharmacokinetics of IV SPR741.

Spero is developing antibiotics for drug-resistant pathogens, as well as potentiators to broaden the spectrum and increase the potency of antibiotics. Next half, Spero plans to start a Phase II trial of SPR741 in combination with a general antibiotic to treat complicated urinary tract infections (cUTIs)...